BHCM
CAI

Brevan Howard Capital Management’s Caris Life Sciences CAI Stock Holding History

Brevan Howard Capital Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Buy
+34,868
New +$624K ﹤0.01% 1333
2026
Q1 		– Sell
-9,767
Closed -$264K – 2583
2025
Q4 		$264K Buy
+9,767
New +$275K ﹤0.01% 1438

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Brevan Howard Capital Management's CAI Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Caris Life Sciences (CAI) in Q2 2026: 34,868 shares worth $621K. The stake represents ﹤0.01% of the portfolio and ranks #1333 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in CAI as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in CAI in Q4 2025 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Brevan Howard Capital Management held 34,868 shares of Caris Life Sciences worth $621K as of Q2 2026.
  • Caris Life Sciences was a new Brevan Howard Capital Management position in Q2 2026.
  • Caris Life Sciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1333 holding.
  • Brevan Howard Capital Management first reported a position in Caris Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.